1089

Pegfilgrastim

(Pegylated recombinant methionyl human granulocyte-colony stimulating factor)

- **INDICATIONS AND DOSE**

Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)

- BY SUBCUTANEOUS INJECTION
- Adult: 6 mg for each chemotherapy cycle, to be given at least 24 hours after chemotherapy, dose is expressed as filgrastim

- **CAUTIONS** Acute leukaemia · myelosuppressive chemotherapy
- **SIDE-EFFECTS**
- **Common or very common** Myalgia · nausea
- **Uncommon** Glomerulonephritis

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- **Neulasta** (Amgen Ltd)
  Filgrastim (as Pegfilgrastim) 10 mg per 1 ml Neulasta 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection PoM £686.38
  Neulasta 6mg/0.6ml solution for injection pre-filled syringes with Onpro kit | 1 pre-filled disposable injection PoM £686.38 (Hospital only)
- **Pelgraz** (Accord Healthcare Ltd) ▼
  Filgrastim (as Pegfilgrastim) 10 mg per 1 ml Pelgraz 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection PoM £686.37 (Hospital only)
- **Pelmeg** (Napp Pharmaceuticals Ltd) ▼
  Filgrastim (as Pegfilgrastim) 10 mg per 1 ml Pelmeg 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection PoM £411.83 (Hospital only)
- **Ziextenzo** (Sandoz Ltd) ▼
  Filgrastim (as Pegfilgrastim) 10 mg per 1 ml Ziextenzo 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection PoM £617.74

3.2 Stem cell mobilisation

IMMUNOSTIMULANTS › CHEMOKINE RECEPTOR ANTAGONISTS

Plerixafor

13-Mar-2020

- **DRUG ACTION** Plerixafor is a chemokine receptor antagonist.

- **INDICATIONS AND DOSE**

Mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or multiple myeloma (specialist use only)

- BY SUBCUTANEOUS INJECTION
- Adult (body-weight up to 84 kg): 240 micrograms/kg daily, alternatively 20 mg daily usually for 2–4 days (and up to 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day
- Adult (body-weight 84 kg and above): 240 micrograms/kg daily usually for 2–4 days (and up to 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day

- **SIDE-EFFECTS**
- **Common or very common** Arthralgia · constipation · diarrhoea · dizziness · dry mouth · erythema · fatigue · flatulence · gastrointestinal discomfort · headache · hyperhidrosis · malaise · musculoskeletal pain · nausea · oral hypoaesthesia · sleep disorders · vomiting
- **Frequency not known** Postural hypotension · splenomegaly · syncope

- **CONCEPTION AND CONTRACEPTION** Use effective contraception during treatment— teratogenic in *animal* studies.
- **PREGNANCY** Manufacturer advises avoid unless essential— teratogenic in *animal* studies.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** No information available if creatinine clearance less than 20 mL/minute.
  Dose adjustments Manufacturer advises reduce dose to 160 micrograms/kg (maximum 27 mg) daily if creatinine clearance 20–50 mL/minute.
- **MONITORING REQUIREMENTS** Monitor platelets and white blood cell count.
- **PATIENT AND CARER ADVICE**
  Driving and skilled tasks Manufacturer advises patients and carers should be cautioned on the effects on driving and performance of skilled tasks—increased risk of dizziness, fatigue, or vasovagal reactions.
- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) decisions
SMC No. 594/09
The *Scottish Medicines Consortium* has advised (January 2010) that plerixafor (*Mozobil*®) is accepted for use within NHS Scotland in combination with granulocyte-colony stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.

All Wales Medicines Strategy Group (AWMSG) decisions
AWMSG No. 249
The *All Wales Medicines Strategy Group* has advised (April 2010) that plerixafor (*Mozobil*®) is recommended as an option for restricted use within NHS Wales in combination with granulocyte-colony stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. Plerixafor (*Mozobil*®) should be restricted for use specifically in patients with non-Hodgkin's lymphoma and multiple myeloma who have already failed one complete mobilisation attempt. The AWMSG is of the opinion that plerixafor (*Mozobil*®) is not suitable for shared care within NHS Wales.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- **Mozobil** (Sanofi)
  Plerixafor 20 mg per 1 ml Mozobil 24mg/1.2ml solution for injection vials | 1 vial PoM £4,882.77